TY - JOUR
T1 - Burden of tracheal, bronchus, and lung cancer in North Africa and Middle East countries, 1990 to 2019
T2 - Results from the GBD study 2019
AU - GBD 2019 NAME Tracheal, Bronchus and Lung Cancer Collaborators
AU - Khanmohammadi, Shaghayegh
AU - Moghaddam, Sahar Saeedi
AU - Azadnajafabad, Sina
AU - Rezaei, Negar
AU - Esfahani, Zahra
AU - Rezaei, Nazila
AU - Naghavi, Mohsen
AU - Larijani, Bagher
AU - Farzadfar, Farshad
AU - Abbasi-Kangevari, Mohsen
AU - Abbasi-Kangevari, Zeinab
AU - Abdoun, Meriem
AU - Abidi, Hassan
AU - Abrehdari-Tafreshi, Zahra
AU - Abu-Zaid, Ahmed
AU - Ahmad, Aqeel
AU - Ahmadi, Sepideh
AU - Hamad, Hanadi Al
AU - Alessy, Saleh Ali
AU - Aljunid, Syed Mohamed
AU - Amir-Behghadami, Mehrdad
AU - Ansari-Moghaddam, Alireza
AU - Arabloo, Jalal
AU - Azangou-Khyavy, Mohammadreza
AU - Baghcheghi, Nayereh
AU - Bajbouj, Khuloud
AU - Bijani, Ali
AU - Bilalaga, Mariah Malak
AU - Bouaoud, Souad
AU - Calina, Daniela
AU - Cho, William C.S.
AU - Da’Ar, Omar B.
AU - Djalalinia, Shirin
AU - Elghazaly, Hesham
AU - Feizkhah, Alireza
AU - Ghashghaee, Ahmad
AU - Golitaleb, Mohamad
AU - Avval, Atlas Haddadi
AU - Hafezi-Nejad, Nima
AU - Hamadeh, Randah R.
AU - Jalili, Mahsa
AU - Jamshidi, Elham
AU - Karimi, Amirali
AU - Khader, Yousef Saleh
AU - Khanali, Javad
AU - Kompani, Farzad
AU - Koohestani, Hamid Reza
AU - Bicer, Burcu Kucuk
AU - Mafi, Ahmad R.
AU - Moraga, Paula
N1 - Publisher Copyright:
Copyright © 2023 Khanmohammadi, Saeedi Moghaddam, Azadnajafabad, Rezaei, Esfahani, Rezaei, GBD 2019 NAME Tracheal, Bronchus and Lung Cancer Collaborators, Naghavi, Larijani and Farzadfar.
PY - 2023/2/10
Y1 - 2023/2/10
N2 - Objective: To provide estimates on the regional and national burden of tracheal, bronchus, and lung (TBL) cancer and its attributable risk factors from 1990 to 2019 in the North Africa and Middle East (NAME) region. Methods and materials: The Global Burden of Disease (GBD) 2019 data were used. Disability-adjusted life years (DALYs), death, incidence, and prevalence rates were categorized by sex and age groups in the NAME region, in 21 countries, from 1990 to 2019. Decomposition analysis was performed to calculate the proportion of responsible factors in the emergence of new cases. Data are presented as point estimates with their 95% uncertainty intervals (UIs). Results: In the NAME region, TBL cancer caused 15,396 and 57,114 deaths in women and men, respectively, in 2019. The age-standardized incidence rate (ASIR) increased by 0.7% (95% UI -20.6 to 24.1) and reached 16.8 per 100,000 (14.9 to 19.0) in 2019. All the age-standardized indices had a decreasing trend in men and an increasing trend in women from 1990 to 2019. Turkey (34.9 per 100,000 [27.6 to 43.5]) and Sudan (8.0 per 100,000 [5.2 to 12.5]) had the highest and lowest age-standardized prevalence rates (ASPRs) in 2019, respectively. The highest and lowest absolute slopes of change in ASPR, from 1990 to 2019, were seen in Bahrain (-50.0% (-63.6 to -31.7)) and the United Arab Emirates (-1.2% (-34.1 to 53.8)), respectively. The number of deaths attributable to risk factors was 58,816 (51,709 to 67,323) in 2019 and increased by 136.5%. Decomposition analysis showed that population growth and age structure change positively contributed to new incident cases. More than 80% of DALYs could be decreased by controlling risk factors, particularly tobacco use. Conclusion: The incidence, prevalence, and DALY rates of TBL cancer increased, and the death rate remained unchanged from 1990 to 2019. All the indices and contribution of risk factors decreased in men but increased in women. Tobacco is still the leading risk factor. Early diagnosis and tobacco cessation policies should be improved.
AB - Objective: To provide estimates on the regional and national burden of tracheal, bronchus, and lung (TBL) cancer and its attributable risk factors from 1990 to 2019 in the North Africa and Middle East (NAME) region. Methods and materials: The Global Burden of Disease (GBD) 2019 data were used. Disability-adjusted life years (DALYs), death, incidence, and prevalence rates were categorized by sex and age groups in the NAME region, in 21 countries, from 1990 to 2019. Decomposition analysis was performed to calculate the proportion of responsible factors in the emergence of new cases. Data are presented as point estimates with their 95% uncertainty intervals (UIs). Results: In the NAME region, TBL cancer caused 15,396 and 57,114 deaths in women and men, respectively, in 2019. The age-standardized incidence rate (ASIR) increased by 0.7% (95% UI -20.6 to 24.1) and reached 16.8 per 100,000 (14.9 to 19.0) in 2019. All the age-standardized indices had a decreasing trend in men and an increasing trend in women from 1990 to 2019. Turkey (34.9 per 100,000 [27.6 to 43.5]) and Sudan (8.0 per 100,000 [5.2 to 12.5]) had the highest and lowest age-standardized prevalence rates (ASPRs) in 2019, respectively. The highest and lowest absolute slopes of change in ASPR, from 1990 to 2019, were seen in Bahrain (-50.0% (-63.6 to -31.7)) and the United Arab Emirates (-1.2% (-34.1 to 53.8)), respectively. The number of deaths attributable to risk factors was 58,816 (51,709 to 67,323) in 2019 and increased by 136.5%. Decomposition analysis showed that population growth and age structure change positively contributed to new incident cases. More than 80% of DALYs could be decreased by controlling risk factors, particularly tobacco use. Conclusion: The incidence, prevalence, and DALY rates of TBL cancer increased, and the death rate remained unchanged from 1990 to 2019. All the indices and contribution of risk factors decreased in men but increased in women. Tobacco is still the leading risk factor. Early diagnosis and tobacco cessation policies should be improved.
KW - attributable risks
KW - bronchus cancer
KW - death
KW - global burden of disease
KW - incidence
KW - lung neoplasms
KW - tobacco use
KW - tracheal cancer
UR - http://www.scopus.com/inward/record.url?scp=85148745022&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.1098218
DO - 10.3389/fonc.2022.1098218
M3 - Article
C2 - 36844919
AN - SCOPUS:85148745022
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1098218
ER -